Local immunomodulation with CD4 and CD8 antibodies, but not cyclosporine A, improves osteogenesis induced by ADhBMP9 gene therapy

Gene Therapy

Volumn 12, Issue 16, 2005, Pages 1235-1241

  Li, J Z ^a   Li, H ^a,b   Hankins, G R ^a   Dunford, B ^a   Helm, G A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; Bone morphogenetic proteins; CD4 and CD8 antibodies; Cyclosporine A; Immunomodulation; Osteogenic

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 9; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; OKT 4; OKT 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENE THERAPY; HISTOLOGY; IMMUNE DEFICIENCY; IMMUNOMODULATION; LEUKOCYTE COUNT; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; AUTOANTIBODIES; BONE MORPHOGENETIC PROTEINS; COMBINED MODALITY THERAPY; CYCLOSPORINE; GENE THERAPY; GENETIC VECTORS; HINDLIMB; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; LEUKOCYTE COUNT; OSTEOGENESIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 23944447628     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302502     Document Type: Article

References (41)

1. Wozney JM. The bone morphogenetic protein family: multi-functional cellular regulators in the embryo and adult. Eur J Oral Sci 1998; 106 (Suppl 1): 160-166.
2. Ducy P, Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000; 57: 2207-2214.
3. Nakashima M, Reddi AH. The application of bone morphogenetic proteins to dental tissue engineering. Nat Biotechnol 2003; 21: 1025-1032.
4. Sheehan JP et al. The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model. J Neurosurg 2003; 98: 125-130.
5. Boden SD. Clinical application of the BMPs. J Bone Joint Surg Am 2001; 83-A (Suppl 1): S161.
6. Li JZ et al. Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Therapy 2003; 10: 1735-1743.
7. Cheng H et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003; 85-A: 1544-1552.
8. Chen Y et al. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Therapy 2003; 10: 1345-1353.
9. Musgrave DS et al. Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. J Bone Joint Surg Br 2002; 84: 120-127.
10. Alden TD et al. In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum Gene Ther 1999; 10: 2245-2253.
11. Kaihara S et al. Simple and effective osteoinductive gene therapy by local injection of a bone morphogenetic protein-2-expressing recombinant adenoviral vector and FK506 mixture in rats. Gene Therapy 2004; 11: 439-447.
12. Okubo Y et al. The time course study of osteoinduction by bone morphogenetic protein-2 via adenoviral vector. Life Sci 2001; 70: 325-336.
13. Russell RG, Graveley R, Skjodt H. The effects of cyclosporin A on bone and cartilage. Br J Rheumatol 1993; 32 (Suppl 1) 42-46.
14. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20: 108-125.
15. Jane Jr JA et al. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 2002; 6: 464-470.
16. Li JZ et al. Osteogenesis in rats induced by a novel recombinant helper-dependent bone morphogenetic protein-9 (BMP-9) adenovirus. J Gene Med 2003; 5: 748-756.
17. Russell G et al. Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum 1992; 21: 16-22.
18. Russell RG et al. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand J Rheumatol Suppl 1992; 95: 9-18.
19. Li JZ et al. Rat strain differences in the ectopic osteogenic potential of recombinant human BMP adenoviruses. Mol Ther 2003; 8: 822-829.
20. Nohe A, Keating E, Knaus P, Petersen NO. Signal transduction of bone morphogenetic protein receptors. Cell Signal 2004; 16: 291-299.
21. Miller AF, Harvey SA, Thies RS, Olson MS. Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J Biol Chem 2000; 275: 17937-17945.
22. Lopez-Coviella I, Berse B, Thies RS, Krzysztof Blusztajn J. Upregulation of acetylcholine synthesis by bone morphogenetic protein 9 in a murine septal cell line. J Physiol Paris 2002; 96: 53-59.
23. Varady P et al. Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum Gene Ther 2001; 12: 697-710.
24. Goodman GR et al. Transforming growth factor-beta administration modifies cyclosporine A-induced bone loss. Bone 2001; 28: 583-588.
25. Goodman GR et al. Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat. Bone 1999; 25: 459-463.
26. Mann GN et al. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 1994; 135: 1077-1083.
27. Kvien TK et al. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 2002; 61: 511-516.
28. Gowen M, MacDonald BR, Russell RG. Actions of recombinant human gamma-interferon and tumor necrosis factor alpha on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro. Arthritis Rheum 1988; 31: 1500-1507.
29. Evans DB, Bunning RA, Van Damme J, Russell RG. Natural human IL-1 beta exhibits regulatory actions on human bone-derived cells in vitro. Biochem Biophys Res Commun 1989; 159: 1242-1248.
30. Evans DB, Bunning RA, Russell RG. The effects of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on human osteoblast-like cells. Biochem Biophys Res Commun 1989; 160: 588-595.
31. Evans DB, Bunning RA, Russell RG. The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun 1990; 166: 208-216.
32. Epstein S et al. Effect of the interaction of parathyroid hormone and cyclosporine a on bone mineral metabolism in the rat. Calcif Tissue Int 2001; 68: 240-247.
33. Awumey EM et al. Molecular and functional evidence for calcineurin-A alpha and beta isoforms in the osteoclast: novel insights into cyclosporin A action on bone resorption. Biochem Biophys Res Commun 1999; 254: 248-252.
34. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-713.
35. Miyazawa K et al. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002; 7: 1191-1204.
36. Funaba M, Zimmerman CM, Mathews LS. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem 2002; 277: 41361-41368.
37. Zimmerman CM, Kariapper MS, Mathews LS. Smad proteins physically interact with calmodulin. J Biol Chem 1998; 273: 677-680.
38. Kaihara S et al. Effect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2. Life Sci 2002; 72: 247-256.
39. Nassar CA et al. Effect of cyclosporin A on alveolar bone homeostasis in a rat periodontitis model. J Periodontal Res 2004; 39: 143-148.
40. Lallemand F et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003; 56: 307-318.
41. Shi W et al. Effect of macrophage-derived apolipoprotein E on established atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 2261-2266.